Photo: Depositphotos
Aug 1, 2025, 20:38
Mark Yarchoan: More Disappointing News in Hepatocellular Carcinoma
Mark Yarchoan, Associate Professor at Johns Hopkins Hospital, shared a recent article by him and colleagues on X:
“More disappointing news in HCC: Adjuvant pembrolizumab failed to beat surveillance in the global P3 KEYNOTE-937 trial (NCT03867084). Merck disclosed the negative result quietly in an SEC filing. Not unexpected after IMbrave050.”
More posts featuring Mark Yarchoan.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 2, 2025, 00:00
Aug 1, 2025, 20:38
Aug 1, 2025, 19:24
Aug 1, 2025, 19:14